Corline Biomedical AB signed a letter of intent with Nuffield Department of Surgical Sciences at the university of Oxford, to evaluate a partnership for clinical studies in type I diabetes. Under the terms of the agreement, Corline Biomedical transfer the technology to treat oceller with Cytoparin, as well as providing regulatory support, while the Nuffield Department of Surgical Sciences in Oxford conducting Cytoparin-the treatment of ocellerna, and recruit and treat patients within the framework of the clinical study. Corline Biomedical retains continued all the commercial rights related to the product. Technology transfer and contacts with regulatory authorities is scheduled to commence after the summer of 2017, at which time a formal agreement between the parties is expected to be in place. This agreement will enable Corline Biomedical and Nuffield Department of Surgical Sciences to evaluate clinical study in type I diabetes.